The UK and US have signed a landmark trade agreement that will guarantee no tariffs on British drug shipments going into the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to increase funding on drugs through the NHS. This commitment guarantees that import taxes on these vital exports will stay at nothing for a timeframe of the next three years.
This development comes after recent warnings to dramatically increase tariffs on patented drug products, with figures discussed up to double the cost.
"This agreement between the Britain reinforces the worldwide climate for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. medicine commerce," an announcement declared.
Commercial Importance
Medicines represent one of the the United Kingdom's most significant goods shipped to the US, which is clearly the largest market for leading companies like GSK and AstraZeneca.
Trade data indicate that in the year to the end of the third quarter, the UK exported pharmaceutical products worth £11.1bn to the US. This figure accounted for a significant portion of all goods exports in that period.
"This deal protects work, stimulates capital expenditure and paves the way for the UK to become a international leader for medical research," a government official commented.
Specific UK Commitments
The deal involves several specific commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new treatments to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to increase total public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum drug companies must pay back to the NHS to stay within budget will be capped at fifteen percent. Last year, refunds exceeded twenty percent.
Recent Tensions
This agreement takes place against a protracted dispute between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
The disagreement were heightened by assertions that US consumers were charged significantly more for the same drugs than people in the Britain and the EU.
In recent months, several major manufacturing plans in the UK have been halted or cancelled, while substantial funding commitments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had declined as a share of its total funding over the previous ten-year period.
